Ads
related to: fda approved intrathecal drugs for prostate cancer patients should avoid- HCP Resources
Useful Resources about XTANDI® for
Your Office and Your Patients
- Important Safety Info
Safety Profile & Adverse Reactions
For XTANDI® (enzalutamide).
- XTANDI® EMBARK Data
Review Xtandi EMBARK Trial Data and
Results.
- XTANDI® FAQs For HCPs
Explore FAQs for Providers & Better
Prepare Your Patients.
- HCP Resources
perfectfaqs.com has been visited by 100K+ users in the past month
Search results
Results from the WOW.Com Content Network
Gallium (68 Ga) gozetotide or Gallium (68 Ga) PSMA-11 sold under the brand name Illuccix among others, is a radiopharmaceutical made of 68 Ga conjugated to prostate-specific membrane antigen (PSMA) targeting ligand, Glu-Urea-Lys(Ahx)-HBED-CC, used for imaging prostate cancer by positron emission tomography (PET). [11]
It is a microtubule inhibitor, [2] and the fourth taxane to be approved as a cancer therapy. [citation needed] Cabazitaxel was developed by Sanofi-Aventis and was approved by the US Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer in June 2010. [5] [6] [7] It is available as a generic medication. [8] [9]
Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. [2] [9] It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), [2] nonmetastatic castration-resistant prostate cancer, [2] and metastatic castration-sensitive prostate ...
Abiraterone acetate was FDA approved in April 2011 for treatment of castration-resistant prostate cancer for patients who have failed docetaxel therapy. Abiraterone acetate inhibits an enzyme known as CYP17, which is used in the body to produce testosterone.
Apalutamide was first described in 2007, and was approved for the treatment of prostate cancer in February 2018. [ 8 ] [ 9 ] [ 10 ] [ 15 ] It is the first medication to be approved specifically for the treatment of non-metastatic castration-resistant prostate cancer.
Zoledronic acid is used to prevent bone fractures in patients with cancers such as multiple myeloma and prostate cancer, as well as for treating osteoporosis. [10] It can also be used to treat hypercalcaemia of malignancy and can be helpful for treating pain from bone metastases. [11] It can be given at home rather than in hospital.
In the early 1990s, the U.S. Food and Drug Administration approved a test called the PSA—or prostate-specific antigen—for early detection of prostate cancer. The simple blood draw detects a ...
Tazemetostat, sold under the brand name Tazverik, is a medication used for the treatment of adults and adolescents aged 16 years and older with metastatic (when cancer cells spread to other parts of the body) or locally advanced (when cancer has grown outside the organ it started in, but has not yet spread to distant parts of the body) epithelioid sarcoma not eligible for complete resection ...
Ads
related to: fda approved intrathecal drugs for prostate cancer patients should avoidperfectfaqs.com has been visited by 100K+ users in the past month